Navigation Links
Valeant Pharmaceuticals Completes Sale Of Filler And Toxin Assets To Galderma
Date:7/10/2014

LAVAL, Quebec, July 10, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash, pursuant to the previously announced agreement with Nestle S.A, which recently completed its acquisition of Galderma.

"We are pleased to complete the divestiture of our products to a company that is firmly committed to the aesthetic dermatology market," said J. Michael Pearson, chairman and chief executive officer.  "Humberto Antunes, CEO of Galderma, has embraced our commercial team and I know he will continue our efforts to build strong relationships with the healthcare leaders in this industry."

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Contact Information:

Laurie W. Little
949-461-6002
laurie.little@valeant.com

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc.
2. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
3. Valeant Pharmaceuticals To Present At Industry Conferences
4. Valeant Pharmaceuticals Agrees to Acquire Solta Medical for $2.92 Per Share in Cash
5. Valeant Pharmaceuticals Announces Redemption Of The Remaining $465.5 Million Aggrerate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
6. Valeant Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes
7. Valeant Pharmaceuticals Announced Redemption Of $450 Million Aggregate Principal Amount Of Its Outstanding 6.50% Senior Notes Due 2016
8. Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. Valeant Pharmaceuticals Announces Partnership With National Coalition Against Domestic Violence
11. Valeant Pharmaceuticals Announces Continuance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., ... case series to be presented at the 2017 National ... begins today and continues through April 22. Physicians will ... , used to assess risk for acute kidney injury ... heart failure (ADHF). Elevated levels of ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc. and ... started in 2016, in which Socionext extracts and ... The companies achieved initial results in reading ultrasound ... Artificial Brain SOINN. The results will be introduced ... April 19-21, at booths 4505 & 4507. ...
(Date:4/18/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company founded ... infections, will present preclinical data supporting the use of ... (MDR) Gram-negative infections at the 27th European Congress of ... in Vienna, Austria . ... "Our ongoing preclinical ...
Breaking Medicine Technology:
(Date:4/22/2017)... ... 2017 , ... Ecommerce sales have grown every year since the 1990’s, with ... The consequences of rapid innovation and growth are often neglected in the name of ... business and individual’s job to give something back to the planet that provides the ...
(Date:4/21/2017)... ... April 21, 2017 , ... An April 10 article in ... teeth, which reveal a great deal about prehistoric ice-age dental practitioners and their primitive ... been used to remove decayed dental matter, and that teeth were then filled with ...
(Date:4/21/2017)... CITY, Utah (PRWEB) , ... April 21, 2017 ... ... of wilderness therapy treatment for adolescents and young adults, has kicked off its ... 20th-Sunday, April 23rd. This year’s theme is “Attachment Informed Therapy for Mental ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is ... overcome their mental health struggles. The Alive team uses advanced behavioral sciences treatment ... in dealing with a mental health struggle is based on 10 modalities of ...
Breaking Medicine News(10 mins):